HLA-B and acute myeloid leukemia: There was also a notable OS advantage for AML NPM1mut patients who expressed one of these depleted haplotypes (p = 0.02), suggesting that HLA-B*07, B*18 and B*40 are more effective at generating an anti-leukemia immune response.